vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and HCI Group, Inc. (HCI). Click either name above to swap in a different company.
HCI Group, Inc. is the larger business by last-quarter revenue ($246.2M vs $196.0M, roughly 1.3× Axsome Therapeutics, Inc.). HCI Group, Inc. runs the higher net margin — 39.7% vs -14.6%, a 54.2% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 52.1%). HCI Group, Inc. produced more free cash flow last quarter ($440.8M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 9.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
HCI Equity Partners is a Washington, DC–based private equity firm with an additional office in Chicago, Illinois.
AXSM vs HCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $246.2M |
| Net Profit | $-28.6M | $97.7M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 58.5% |
| Net Margin | -14.6% | 39.7% |
| Revenue YoY | 65.0% | 52.1% |
| Net Profit YoY | 61.9% | 3679.2% |
| EPS (diluted) | $-0.55 | $7.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $246.2M | ||
| Q3 25 | $171.0M | $216.3M | ||
| Q2 25 | $150.0M | $221.9M | ||
| Q1 25 | $121.5M | $216.4M | ||
| Q4 24 | $118.8M | $161.9M | ||
| Q3 24 | $104.8M | $175.3M | ||
| Q2 24 | $87.2M | $206.2M | ||
| Q1 24 | $75.0M | $206.6M |
| Q4 25 | $-28.6M | $97.7M | ||
| Q3 25 | $-47.2M | $65.5M | ||
| Q2 25 | $-48.0M | $66.2M | ||
| Q1 25 | $-59.4M | $69.7M | ||
| Q4 24 | $-74.9M | $2.6M | ||
| Q3 24 | $-64.6M | $5.7M | ||
| Q2 24 | $-79.3M | $54.1M | ||
| Q1 24 | $-68.4M | $47.6M |
| Q4 25 | -13.8% | 58.5% | ||
| Q3 25 | -27.0% | 41.9% | ||
| Q2 25 | -24.5% | 42.5% | ||
| Q1 25 | -46.9% | 46.4% | ||
| Q4 24 | -61.1% | 3.6% | ||
| Q3 24 | -59.8% | 8.0% | ||
| Q2 24 | -89.5% | 36.9% | ||
| Q1 24 | -89.7% | 37.5% |
| Q4 25 | -14.6% | 39.7% | ||
| Q3 25 | -27.6% | 30.3% | ||
| Q2 25 | -32.0% | 29.8% | ||
| Q1 25 | -48.9% | 32.2% | ||
| Q4 24 | -63.1% | 1.6% | ||
| Q3 24 | -61.7% | 3.2% | ||
| Q2 24 | -91.0% | 26.2% | ||
| Q1 24 | -91.1% | 23.0% |
| Q4 25 | $-0.55 | $7.29 | ||
| Q3 25 | $-0.94 | $4.90 | ||
| Q2 25 | $-0.97 | $5.18 | ||
| Q1 25 | $-1.22 | $5.35 | ||
| Q4 24 | $-1.54 | $0.32 | ||
| Q3 24 | $-1.34 | $0.52 | ||
| Q2 24 | $-1.67 | $4.24 | ||
| Q1 24 | $-1.44 | $3.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $1.2B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.0B |
| Total Assets | $689.8M | $2.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $1.2B | ||
| Q3 25 | $325.3M | $987.9M | ||
| Q2 25 | $303.0M | $947.2M | ||
| Q1 25 | $300.9M | $754.5M | ||
| Q4 24 | $315.4M | $532.5M | ||
| Q3 24 | $327.3M | $518.8M | ||
| Q2 24 | $315.7M | $445.8M | ||
| Q1 24 | $331.4M | $655.4M |
| Q4 25 | $88.3M | $1.0B | ||
| Q3 25 | $73.7M | $821.8M | ||
| Q2 25 | $73.1M | $758.6M | ||
| Q1 25 | $53.2M | $522.7M | ||
| Q4 24 | $57.0M | $453.3M | ||
| Q3 24 | $92.9M | $455.3M | ||
| Q2 24 | $102.9M | $447.3M | ||
| Q1 24 | $144.0M | $395.7M |
| Q4 25 | $689.8M | $2.5B | ||
| Q3 25 | $669.3M | $2.3B | ||
| Q2 25 | $639.8M | $2.4B | ||
| Q1 25 | $596.7M | $2.3B | ||
| Q4 24 | $568.5M | $2.2B | ||
| Q3 24 | $561.5M | $2.0B | ||
| Q2 24 | $548.2M | $1.9B | ||
| Q1 24 | $545.7M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $444.4M |
| Free Cash FlowOCF − Capex | $-18.7M | $440.8M |
| FCF MarginFCF / Revenue | -9.6% | 179.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.5% |
| Cash ConversionOCF / Net Profit | — | 4.55× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $771.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $444.4M | ||
| Q3 25 | $1.0M | $26.7M | ||
| Q2 25 | $-32.4M | $145.0M | ||
| Q1 25 | $-43.4M | $162.0M | ||
| Q4 24 | $-26.2M | $331.8M | ||
| Q3 24 | $-18.6M | $104.1M | ||
| Q2 24 | $-30.1M | $-29.0M | ||
| Q1 24 | $-53.5M | $182.0M |
| Q4 25 | $-18.7M | $440.8M | ||
| Q3 25 | $988.0K | $25.9M | ||
| Q2 25 | $-32.4M | $144.5M | ||
| Q1 25 | $-43.7M | $160.3M | ||
| Q4 24 | $-26.2M | $327.8M | ||
| Q3 24 | $-18.7M | $103.2M | ||
| Q2 24 | $-30.2M | $-30.1M | ||
| Q1 24 | $-53.6M | $181.0M |
| Q4 25 | -9.6% | 179.0% | ||
| Q3 25 | 0.6% | 12.0% | ||
| Q2 25 | -21.6% | 65.1% | ||
| Q1 25 | -36.0% | 74.1% | ||
| Q4 24 | -22.1% | 202.5% | ||
| Q3 24 | -17.9% | 58.9% | ||
| Q2 24 | -34.6% | -14.6% | ||
| Q1 24 | -71.4% | 87.6% |
| Q4 25 | 0.0% | 1.5% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 0.5% |
| Q4 25 | — | 4.55× | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 2.19× | ||
| Q1 25 | — | 2.32× | ||
| Q4 24 | — | 128.41× | ||
| Q3 24 | — | 18.33× | ||
| Q2 24 | — | -0.54× | ||
| Q1 24 | — | 3.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
HCI
| Insurance Operation | $218.3M | 89% |
| Reciprocal Exchange Operation | $27.0M | 11% |
